Novavax and CureVac among several biotechs with new CEOs; Michel Vounatsos, John Tsai land board appointments
→ Stanley Erck finally crossed a regulatory goal line at Novavax. And now he’s ready to walk off the field for the last time as CEO.
Erck will retire on Jan. 23 and will look on from the sidelines in an advisory role until next year, according to a press release. Harmony Biosciences president and CEO John Jacobs, a Pfizer and Teva vet, is poised to take over for Erck.
Novavax opened its doors in 1987 but didn’t have a single FDA success to its name until its protein-based Covid-19 vaccine secured an EUA in July 2022 — and that road wasn’t free from obstacles either. “My experience at Novavax, especially leading the company in the global pandemic response, has been the highlight of my 40-year career as a biotechnology leader,” said Erck, who was named CEO nearly 12 years ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.